Alvesco, Tentavir Inhaler (Ciclesonide) - Dose, Side effects

Alvesco inhaler (Tentavir inhaler) contains ciclesonide, a prodrug that is activated in the body. It is a potent steroid used for maintenance and prophylactic therapy via the inhalational route in patients with Asthma. It should not be advised to patients with acute severe asthma.

Ciclesonide (oral inhalation) Dose in Adults

Note: Titrate to the lowest effective dose once asthma stability is achieved.

Alvesco inhaler (Tentavir inhaler) dose in Asthma:

Note: Dependent on the severity of the asthma and the previous asthma treatment. In patients who are not well managed after 4 weeks of medication, the dose may be increased.

  • Prior therapy with bronchodilators alone:

    • 80 mcg twice daily to a maximum dose of 160 mcg twice daily
  • Prior therapy with inhaled corticosteroids:

    • 80 mcg twice daily to a maximum dose of 320 mcg twice daily
  • Prior therapy with oral corticosteroids:

    • 320 mcg twice daily to a maximum dose of 320 mcg twice daily.

Asthma guidelines: Global Initiative for Asthma guidelines (HFA inhaler):

Metered dose Alvesco (Tentavir) inhaler:

  • Low-dose therapy:

    • 80 to 160 mcg/day in divided doses twice daily
  • Medium-dose therapy:

    • greater than 160 to 320 mcg/day in divided doses twice daily
  • High-dose therapy:

    • greater than 320 mcg/day in divided doses twice daily

Conversion from oral to orally-inhaled steroid:

  • At least one week after starting inhaled medication, a patient should start gradually reducing their oral corticosteroid dosage.
  • The dose of oral corticosteroids should not be reduced more rapidly than 2.5 mg per week.

Ciclesonide (oral inhalation) Dose in Childrens

Ciclesonide (Alvesco, Tentavir) use in maintenance therapy of Asthma:

  • Alvesco inhaler comes in two dosages:

    • 80 mcg/inhalation and
    • 160 mcg/inhalation:
  • Children 2 to 11 years:

    • Metered-dose inhaler:
      •  40, 80, or 160 mcg once daily.
  • Children older than 12 years and Adolescents:

    • Prior therapy with bronchodilators alone:

      • 80 mcg two times per day. If the response is insufficient after 4 weeks of therapy, increase the dose. The highest daily dose is 80 mcg twice daily, or 320 mcg per day.
    • Prior therapy with inhaled corticosteroids:

      • If response is insufficient after 4 weeks of therapy, increase the dose up to a daily maximum of 640 mcg.
    • Prior therapy with oral corticosteroids:

      • 320 mcg twice daily to a maximum daily dose of 640 mcg/day
  • Children 6 to 11 years:

    • "Low" dose: 80 mcg/day
    • "Medium" dose: greater than 80 to 160 mcg/day
    • "High" dose: greater than 160 mcg/day
  • Children ≥12 years and Adolescents:

    • "Low" dose: 80 to 160 mcg/day
    • "Medium" dose: greater than 160 to 320 mcg/day
    • "High" dose: greater than 320 mcg/day
  • Children 6 to 11 years (Canadian labeling)

    • 100 to 200 mcg once daily
    • The maintenance dose is 100 to 200 mcg/day
  • Children older than 12 years and Adolescents:

    • 400 mcg once daily
    • Maintenance dose: 100 to 800 mcg/day

Conversion: Conversion from oral to orally-inhaled steroid:

  • Children older than 12 years and Adolescents:
    • At least one week after starting inhaled medication, a patient should start gradually reducing their oral corticosteroid dosage.
    • The dose of oral corticosteroids should not be reduced more rapidly than 2.5 mg per week.

Pregnancy Risk Factor C

  • Uncontrolled asthma can lead to adverse pregnancy events such as preterm births, perinatal mortality, pre-eclampsia and preterm births.
  • Pregnant women may be given inhaled corticosteroids. Inhalational steroids may cause more severe asthma symptoms than those that are controlled.

Use of clesonide during breastfeeding

  • Breastfeeding should be encouraged for people with asthma.
  • Breastfeeding is safe with the use of inhalational steroids.
  • But, it is important to be cautious and monitor the infant for signs of hypercortisolism.

Ciclesonide (oral inhalation) Dose in Kidney Disease:

  • Patients with renal dysfunction have not been investigated when using clesonide.
  • However, since only 20% of the medication is eliminated by the renal system, a dose change may not be required.

Ciclesonide (oral inhalation) dose in Liver Disease:

No dose adjustment required in patients with liver disease.

Common Side Effects of ciclesonide (Alvesco, tentavir inhaler):

  • Central nervous system:

    • Headache
  • Respiratory:

    • Nasopharyngitis

Less Common Side Effects of Alvesco inhaler (ciclesonide, tentavir 160):

  • Cardiovascular:

    • Facial edema
  • Central nervous system:

    • Dizziness
    • Fatigue
    • Voice disorder
  • Dermatologic:

    • Urticaria
  • Gastrointestinal:

    • Gastroenteritis
    • Oral candidiasis
  • Infection:

    • Influenza
  • Neuromuscular & skeletal:

    • Arthralgia
    • Back pain
    • Limb pain
    • musculoskeletal chest pain
  • Ophthalmic:

    • Conjunctivitis
  • Otic:

    • Otalgia
  • Respiratory:

    • Upper respiratory tract infection
    • Nasal congestion
    • Pharyngolaryngeal pain
    • Hoarseness
    • Pneumonia
    • Sinusitis
    • Paradoxical
    • Bronchospasm

Contraindication to Ciclesonide include:

  • Allergy or sensitivity to ciclesonide
  • Any component of the formulation
  • Acute asthma episodes 
  • Untreated fungal, bacterial, or tuberculosis infections of the respiratory tract
  • Moderate to severe bronchiectasis

Warnings and Precautions

  • Suppression of the adrenals:
    • Children under the age of five or individuals taking large doses for extended periods of time may experience hypercortisolism, or suppression of the hypothalamic-pituitary-adrenal (HPA) axis.
    • If the drug is suddenly stopped, HPA axis suppression could cause adrenal crises.
    • It is important to withdraw and stop using a corticosteroid slowly and carefully.
    • Patients who have an acute illness or during the perioperative period should receive intravenous hydrocortisone stress doses.
  • Bronchospasm
    • Paradoxical bronchospasm is a condition that has been reported. It can be hard to distinguish from worsening asthmatic symptoms. It is important to get treatment as soon as possible.
  • Immunosuppression:
    • Corticosteroids can cause immunosuppression, which may increase the risk of infection, especially tuberculosis, fungal and rare viral infections.
    • Steroids can make vaccines less effective.
    • Avoid measles and chickenpox exposure. It is important to get timely immunoglobulins. Antiviral agents may be required if chickenpox is developed.
  • Oral candidiasis:
    • To avoid any oral candidiasis, patients should rinse their mouth with water after using an inhaler.​​​​​​​
  • Vasculitis:
    • If symptoms of asthma persist, you should seek treatment for the churgh–Strauss syndrome.​​​​​​​​​​​​​​
  • Bone mineral density:
    • Patients on long-term steroids should monitor their bone mineral density regularly.​​​​​​​
  • Ocular disease:
    • Regularly monitor your visual acuity, and check for glaucoma or cataracts.

Ciclesonide (oral inhalation): Drug Interaction

Note: Drug Interaction Categories:

  • Risk Factor C: Monitor When Using Combination
  • Risk Factor D: Consider Treatment Modification
  • Risk Factor X: Avoid Concomitant Use

Risk Factor C (Monitor therapy).

Amphotericin B Amphotericin's effects on hypokalemia can be exacerbated by corticosteroids (orally inhaled).
Corticorelin Corticosteroids can reduce the therapeutic effects of Corticorelin. Recent or current corticosteroid treatment may affect plasma ACTH responses to Corticorelin.
Cosyntropin The diagnostic effects of Cosyntropin may be diminished by the use of corticosteroids (orally inhaled).
Deferasirox Corticosteroids can intensify Deferasirox's hazardous or harmful effects. Particularly, there may be a higher risk of GI bleeding or ulcers.
Loop Diuretics Loop Diuretics may be enhanced by the hypokalemic effects of Corticosteroids (orally inhaled).
Ritodrine Ritodrine's toxic/adverse effects may be amplified by corticosteroids.
Thiazide and Thiazide - Like Diuretics The effects of thiazide or thiazide-like diuretics on hypokalemia may be exacerbated by orally inhaled corticosteroids.
Tobacco (Smoked). Corticosteroids (Orally inhaled) may cause a decrease in therapeutic effects

Risk Factor D (Consider therapy modifications)

 
Hyaluronidase The therapeutic effects of Hyaluronidase may be diminished by corticosteroids. Management: Patients who are taking corticosteroids, especially at higher doses, may not have the desired clinical response to standard doses hyaluronidase. Higher doses of hyaluronidase might be necessary.

Risk Factor X (Avoid Combination)

 
Aldesleukin Aldesleukin's antineoplastic effects may be diminished by corticosteroids.
Desmopressin Desmopressin's hyponatremic effects may be enhanced by corticosteroids (orally inhaled).
Loxapine Agents to treat airway disease may increase the toxic/adverse effects of Loxapine. Agents to Treat Airway Disease are likely to be a sign that patients are more likely to experience significant bronchospasm due inhaled loxapine. This applies to Adasuve's inhaled loxapine brand. This does not apply for non-inhaled formulations.

Monitoring parameters while using ciclesonide (Tentavir/ alvesco) inhaler:

  • Forced expiratory volume
  • peak flow rate
  • bone mineral density
  • growth velocity 
  • HPA axis suppression & adrenal insufficiency
  • oral candidiasis
  • asthma
  • glaucoma & cataracts

How to use Ciclesonide metered-dose inhaler (Tentavir 160, Alvesco)?

  • Before using the inhaler for the first time or after more than 10 days without use, prime it by actuating it three times. (Avoid shaking before using)
  • After inhaling, rinse your mouth with water (and spit it out) or use it before meals.
  • Avoid washing or submerging the inhaler in water.
  • Once each week, wipe the mouthpiece with a dry towel or tissue.
  • Even if the canister is not quite empty, throw it away after the "discard by" date or when the dose indicator display window reads "0."

Mechanism of action of Alvesco inhaler (Ciclesonide):

After being administered, Ciclesonide, a glucocorticoid drug, is hydrolyzed to become its active metabolite desciclesonide. Des-ciclesonide is highly attracted to the glucocorticoid hormone receptor. The mechanism of action for corticosteroids is believed to be a combination of three important properties:

  • Anti-inflammatory activity
  • Immunosuppressive properties and
  • Antiproliferative measures

The drug must be taken orally.Maximum benefit can be achieved for up to 4 weeks. Nearly half of the drug is absorbed through the lungs, and 99% is bound to proteins. Hydrolysis of Ciclesonide to des-ciclesonide, its active metabolite via esterases within the nasal mucosa or lungs is how it is metabolized. Further hepatic metabolism occurs via CYP3A4 (and to a lesser degree via CYP2D6). Following are the bioavailabilities of the active drugInhalation is 63%, while oral intake is negligible. Eliminating half-lifeCiclesonide takes 0.7 hours, and des-ciclesonide takes 6 to 7 hours The time it takes for the active drug to reach its peak plasma concentration is1 hour 66% of the drug can be excreted via feces

Ciclesonide inhaler international brands:

  • Alvesco
  • Cesonide
  • Cicletex
  • Ciclocip
  • Ciclohale
  • Ciclotis
  • Disbronc
  • Osonide
  • Tentavir

Ciclesonide (oral inhalation) Brands in Pakistan:

No brands of ciclesonide inhaler are available in Pakistan